// App-Quantinova.ai

e15127 : Can alfa-fetoprotein response to sorafenib predict for response and overall survival in hepatocellular carcinoma?

Researchers

Presenter

  • Humdum Pasha Durrani

Principal Investigators

  • Hemant S. Murthy

  • Prashanti Atluri

  • Sirish Sanaka

  • Punam Punja

  • Salini Sathya Naidu

Medical Centers

  • Vidant Medical Center, Greenville, NC

  • Leo Jenkins Cancer Center Brody School of Medicine at East Carolina University, Greenville, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Alfa-fetoprotein

  • Sorafenib

Outcome

  • Positive

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved